Search Science Hub

Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

ADA 2026 5 - 8 June 2026

High-dose subcutaneous semaglutide is associated with preservation of kidney function in people living with obesity without diabetes

Authors :

Peter Rossing^1,2; Christine Sofie Fuchs Jacobsen³; Jøran Hjelmesæth^4,5; Kristoffer Jensen Kolnes³; Lauren Wilson⁶; Katherine Tuttle^7,8

Affiliations

View Details Hide Details

Download .PDF

Keywords

Obesity

Cardiovascular Disease

Congress poster

GLP-1 RA

Semaglutide

PHASE 3 (RCT)